Lung cancer remains a leading cause of cancer death worldwide, with non-small-cell lung
cancer (NSCLC) accounting for the majority of cases. Immune checkpoint inhibitors (CPIs) …

Herein we trace links between biochemical pathways, pathogenesis, and metabolic
diseases to set the stage for new therapeutic advances. Cellular and acellular …

Background Although the mitogen-activated protein kinases (MAPK) pathway is hyperactive
in head and neck cancer (HNC), inhibition of MEK1/2 in HNC patients has not shown …

Breast cancer is the most common malignancy in women worldwide and despite significant
advancements in detection, treatment, and management of cancer, it is still the leading …

Background The identification of novel therapeutic strategies to overcome resistance to the
MEK inhibitor trametinib in mutant KRAS lung adenocarcinoma (LUAD) is a challenge. This …

Gastroentero-pancreatic Neuroendocrine Neoplasms (GEP-NENs) are a diverse group of
rare tumors that arise from neuroendocrine cells in the gastrointestinal tract and pancreas …

Cancer immunotherapy, or the utilization of components of the immune system to target and
eliminate cancer, has become a highly active area of research in the past several decades …

Recent advances in comprehending the essential molecular mechanisms that govern
cancer signaling have revealed the pivotal involvement of kinases in the development and …

Studies have begun to employ macrophages engineered with chimeric antigen receptor
(CAR-Macs) against solid tumors since they can enter solid tumor tissue and interact with …

Aims Hepatocellular carcinoma (HCC) is still a leading cause of cancer-related death
worldwide. But its chemotherapeutic options are far from expectation. We here compared H …